Eli Lilly Ends Collaboration with Rigel on Ocadusertib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Should l Buy RIGL?
Source: seekingalpha
- Collaboration Termination: Eli Lilly has decided to terminate its license and collaboration agreement with Rigel Pharmaceuticals regarding ocadusertib, effective June 15, 2023, which was initially signed in February 2021, resulting in Rigel no longer receiving any milestone payments and directly impacting its future revenue.
- Rights Reversion: With the termination of the agreement, Rigel Pharmaceuticals will regain all rights to ocadusertib, an oral RIPK1 inhibitor originally developed for autoimmune and inflammatory diseases, potentially providing new opportunities for its subsequent research and development.
- Clinical Trial Progress: As of December 2025, ocadusertib is undergoing a phase 2a clinical trial by Lilly for severe rheumatoid arthritis, and the termination of the collaboration may affect the drug's further development and market prospects.
- Market Reaction: Rigel Pharmaceuticals is experiencing a decline in contract revenue, which may lead to a contraction in its financial status, increasing market attention on its future, especially in the context of the highly competitive biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RIGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RIGL
Wall Street analysts forecast RIGL stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 32.490
Low
38.00
Averages
52.00
High
71.00
Current: 32.490
Low
38.00
Averages
52.00
High
71.00
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Ends Collaboration with Rigel on Ocadusertib
- Collaboration Termination: Eli Lilly has decided to terminate its license and collaboration agreement with Rigel Pharmaceuticals regarding ocadusertib, effective June 15, 2023, which was initially signed in February 2021, resulting in Rigel no longer receiving any milestone payments and directly impacting its future revenue.
- Rights Reversion: With the termination of the agreement, Rigel Pharmaceuticals will regain all rights to ocadusertib, an oral RIPK1 inhibitor originally developed for autoimmune and inflammatory diseases, potentially providing new opportunities for its subsequent research and development.
- Clinical Trial Progress: As of December 2025, ocadusertib is undergoing a phase 2a clinical trial by Lilly for severe rheumatoid arthritis, and the termination of the collaboration may affect the drug's further development and market prospects.
- Market Reaction: Rigel Pharmaceuticals is experiencing a decline in contract revenue, which may lead to a contraction in its financial status, increasing market attention on its future, especially in the context of the highly competitive biopharmaceutical industry.
See More
Rigel Pharmaceuticals Grants Restricted Stock Units to Employees
- Employee Incentive Plan: Rigel Pharmaceuticals has granted 8,925 restricted stock units to six non-executive employees under its Inducement Plan, aimed at attracting and retaining talent to enhance the company's competitive edge.
- Grant Details: The stock units will vest over four years, with 25% vesting each year, which is intended to boost employee long-term commitment and engagement in their roles.
- Compliance Assurance: This grant complies with NASDAQ Listing Rule 5635(c)(4), ensuring the company's adherence to regulatory standards in its incentive measures, thereby enhancing investor confidence.
- Company Background: Founded in 1996, Rigel Pharmaceuticals focuses on developing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer, showcasing its ongoing innovation in the biotechnology sector.
See More
CytomX Therapeutics Stock Surges 44.23% Following Positive Phase 1 Data
- Clinical Data Highlights: CytomX's Phase 1 data for Varseta-M in metastatic colorectal cancer shows an objective response rate of up to 32% and approximately seven months of progression-free survival, enhancing confidence for FDA registrational trial discussions expected in 2026.
- Surge in Trading Volume: The company's trading volume reached 118 million shares on Monday, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market reaction to the new data and potentially attracting more investor interest.
- Transparent Financial Position: CytomX projects approximately $76 million in revenue for 2025, with cash reserves around $137 million, providing funding clarity into the second quarter of 2027, although wider-than-expected losses remind investors of the financial risks associated with clinical progress.
- Positive Market Reaction: CytomX's stock surged 44.23% to $6.75, reflecting investor optimism regarding its clinical advancements, which also positively impacted peer companies like XOMA and Rigel Pharmaceuticals, underscoring broader interest in drug developers.
See More
CytomX Therapeutics Stock Soars 44.23% After Positive Phase 1 Data
- Promising Clinical Data: CytomX's Phase 1 Varseta-M data in metastatic colorectal cancer reveals an objective response rate of 32% and a progression-free survival of approximately seven months, laying a solid foundation for future FDA registrational trial discussions and boosting investor confidence.
- Surge in Trading Volume: On Monday, trading volume reached 118 million shares, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market interest and active investor participation, which could further propel the stock price upward.
- Transparent Financial Outlook: CytomX anticipates approximately $76 million in revenue for 2025, with cash reserves around $137 million, providing financial runway into the second quarter of 2027; however, wider-than-expected losses remind investors of the inherent financial risks associated with clinical progress.
- Positive Market Reaction: Following the data release, analysts reacted positively, driving the stock price up to $6.75, a 44.23% increase from the previous trading day, reflecting strong market interest in the biotech sector and recognition of CytomX's future potential.
See More
CytomX Therapeutics Stock Soars 44.23% After Positive Phase 1 Data
- Promising Clinical Data: CytomX's Phase 1 data for Varseta-M in metastatic colorectal cancer shows an objective response rate of up to 32% and approximately seven months of progression-free survival, bolstering confidence for FDA registrational trial discussions expected in 2026.
- Surge in Trading Volume: The company's trading volume reached 118 million shares on Monday, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market reaction to the new data and potentially attracting more investor interest.
- Solid Financial Position: CytomX anticipates approximately $76 million in revenue for 2025, and while net losses have widened, the company holds around $137 million in cash reserves, ensuring funding needs are met through the second quarter of 2027 to support ongoing oncology programs.
- Positive Market Reaction: Despite a 48% decline in stock price since its 2015 IPO, the recent surge reflects investor optimism about the company's future potential, particularly against the backdrop of strong performance in the biotechnology sector.
See More
Rigel Pharmaceuticals Shares Hit Four-Month Low Amid Revenue Decline Projections
- Revenue Decline Projection: Rigel Pharmaceuticals projects a revenue decline for 2026, estimating total revenue between $275 million and $290 million, which represents a ~4% year-over-year drop from last year's $294.3 million, indicating potential challenges ahead for the company's financial health.
- Sharp Drop in Contract Revenue: The company anticipates contract revenue to be between $20 million and $25 million, implying a staggering ~64% year-over-year decline, highlighting significant challenges in its collaborative partnerships that could impact its competitive position in the biotech sector.
- Product Sales Growth: Despite the overall revenue decline, Rigel expects net product sales to reach approximately $255 million to $265 million, reflecting an ~11% year-over-year increase, suggesting strong market demand for its core products, which may provide some financial stability.
- Earnings Exceed Expectations: Rigel reported Q4 2025 earnings of $13.54 per share on $69.8 million in revenue, both surpassing market expectations, demonstrating effective financial management and cost control, although the outlook remains concerning due to projected declines in revenue.
See More
Eli Lilly Ends Collaboration with Rigel on Ocadusertib
- Collaboration Termination: Eli Lilly has decided to terminate its license and collaboration agreement with Rigel Pharmaceuticals regarding ocadusertib, effective June 15, 2023, which was initially signed in February 2021, resulting in Rigel no longer receiving any milestone payments and directly impacting its future revenue.
- Rights Reversion: With the termination of the agreement, Rigel Pharmaceuticals will regain all rights to ocadusertib, an oral RIPK1 inhibitor originally developed for autoimmune and inflammatory diseases, potentially providing new opportunities for its subsequent research and development.
- Clinical Trial Progress: As of December 2025, ocadusertib is undergoing a phase 2a clinical trial by Lilly for severe rheumatoid arthritis, and the termination of the collaboration may affect the drug's further development and market prospects.
- Market Reaction: Rigel Pharmaceuticals is experiencing a decline in contract revenue, which may lead to a contraction in its financial status, increasing market attention on its future, especially in the context of the highly competitive biopharmaceutical industry.
See More
Rigel Pharmaceuticals Grants Restricted Stock Units to Employees
- Employee Incentive Plan: Rigel Pharmaceuticals has granted 8,925 restricted stock units to six non-executive employees under its Inducement Plan, aimed at attracting and retaining talent to enhance the company's competitive edge.
- Grant Details: The stock units will vest over four years, with 25% vesting each year, which is intended to boost employee long-term commitment and engagement in their roles.
- Compliance Assurance: This grant complies with NASDAQ Listing Rule 5635(c)(4), ensuring the company's adherence to regulatory standards in its incentive measures, thereby enhancing investor confidence.
- Company Background: Founded in 1996, Rigel Pharmaceuticals focuses on developing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer, showcasing its ongoing innovation in the biotechnology sector.
See More
CytomX Therapeutics Stock Surges 44.23% Following Positive Phase 1 Data
- Clinical Data Highlights: CytomX's Phase 1 data for Varseta-M in metastatic colorectal cancer shows an objective response rate of up to 32% and approximately seven months of progression-free survival, enhancing confidence for FDA registrational trial discussions expected in 2026.
- Surge in Trading Volume: The company's trading volume reached 118 million shares on Monday, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market reaction to the new data and potentially attracting more investor interest.
- Transparent Financial Position: CytomX projects approximately $76 million in revenue for 2025, with cash reserves around $137 million, providing funding clarity into the second quarter of 2027, although wider-than-expected losses remind investors of the financial risks associated with clinical progress.
- Positive Market Reaction: CytomX's stock surged 44.23% to $6.75, reflecting investor optimism regarding its clinical advancements, which also positively impacted peer companies like XOMA and Rigel Pharmaceuticals, underscoring broader interest in drug developers.
See More
CytomX Therapeutics Stock Soars 44.23% After Positive Phase 1 Data
- Promising Clinical Data: CytomX's Phase 1 Varseta-M data in metastatic colorectal cancer reveals an objective response rate of 32% and a progression-free survival of approximately seven months, laying a solid foundation for future FDA registrational trial discussions and boosting investor confidence.
- Surge in Trading Volume: On Monday, trading volume reached 118 million shares, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market interest and active investor participation, which could further propel the stock price upward.
- Transparent Financial Outlook: CytomX anticipates approximately $76 million in revenue for 2025, with cash reserves around $137 million, providing financial runway into the second quarter of 2027; however, wider-than-expected losses remind investors of the inherent financial risks associated with clinical progress.
- Positive Market Reaction: Following the data release, analysts reacted positively, driving the stock price up to $6.75, a 44.23% increase from the previous trading day, reflecting strong market interest in the biotech sector and recognition of CytomX's future potential.
See More
CytomX Therapeutics Stock Soars 44.23% After Positive Phase 1 Data
- Promising Clinical Data: CytomX's Phase 1 data for Varseta-M in metastatic colorectal cancer shows an objective response rate of up to 32% and approximately seven months of progression-free survival, bolstering confidence for FDA registrational trial discussions expected in 2026.
- Surge in Trading Volume: The company's trading volume reached 118 million shares on Monday, a staggering 2,211% increase over the three-month average of 5.1 million shares, indicating strong market reaction to the new data and potentially attracting more investor interest.
- Solid Financial Position: CytomX anticipates approximately $76 million in revenue for 2025, and while net losses have widened, the company holds around $137 million in cash reserves, ensuring funding needs are met through the second quarter of 2027 to support ongoing oncology programs.
- Positive Market Reaction: Despite a 48% decline in stock price since its 2015 IPO, the recent surge reflects investor optimism about the company's future potential, particularly against the backdrop of strong performance in the biotechnology sector.
See More
Rigel Pharmaceuticals Shares Hit Four-Month Low Amid Revenue Decline Projections
- Revenue Decline Projection: Rigel Pharmaceuticals projects a revenue decline for 2026, estimating total revenue between $275 million and $290 million, which represents a ~4% year-over-year drop from last year's $294.3 million, indicating potential challenges ahead for the company's financial health.
- Sharp Drop in Contract Revenue: The company anticipates contract revenue to be between $20 million and $25 million, implying a staggering ~64% year-over-year decline, highlighting significant challenges in its collaborative partnerships that could impact its competitive position in the biotech sector.
- Product Sales Growth: Despite the overall revenue decline, Rigel expects net product sales to reach approximately $255 million to $265 million, reflecting an ~11% year-over-year increase, suggesting strong market demand for its core products, which may provide some financial stability.
- Earnings Exceed Expectations: Rigel reported Q4 2025 earnings of $13.54 per share on $69.8 million in revenue, both surpassing market expectations, demonstrating effective financial management and cost control, although the outlook remains concerning due to projected declines in revenue.
See More
